摘要新生血管的发生在恶性肿瘤发生、发展和转移过程起着关键作用.CD13是人类白血病分级的重要谱系特异性标志物,在新生血管内皮细胞上特异性高表达,在静止血管内皮细胞上不表达.利用荧光、核素标记或磁性纳米颗粒耦联CD13单克隆抗体、配体,通过分子成像技术可有效探测新生血管的发生,为研究血管相关疾病的发生、发展提供影像学依据；CD13的配体——天冬氨酸-甘氨酸-精氨酸与各种抗肿瘤药物构成复合物,然后转运到肿瘤新生血管内皮细胞表面与CD13结合,释放抗肿瘤药物治疗肿瘤.CD13在与新生血管相关的各类疾病的认识、诊断、治疗的研究中有着突破性进展和良好的前景.

abstractsThe development and metasis of malignant tumor depend on neovascularization.CD 13 is a significant marker of cells commit to myeloid lineage to classify leukemia,meanwhile it expresses on the neovascular endothelial cells specifically but expresses barely in vascular endothelial cells.Coupling CD13 monoclonal antibody or CD13 ligand to CD13 in fluorescence,radionuclide or magnetic nanoparticles to achieve molecular imaging to probe angiogenesis and provide imaging evidence of the development of angiogenesis associated disease.Asn-Gly-Arg peptide motif compound with different anticancer drugs targeted deliver to neovascular endothelial cells and release the anticancer drugs to treat the tumor.The research of CD13 to understand,diagnose and treat the angiogenesis associated diseases has gotten breakthrough and have a promising future.